Tanvex BioPharma, Inc. (6541.TW)
TWD 61.0
(2.35%)
TWD 61.0
(2.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.94 Billion TWD | -4.24% |
| 2022 | 2.02 Billion TWD | 5.71% |
| 2021 | 1.91 Billion TWD | 9.52% |
| 2020 | 1.75 Billion TWD | 223.18% |
| 2019 | 542.12 Million TWD | 105.41% |
| 2018 | 263.91 Million TWD | 17.93% |
| 2017 | 223.78 Million TWD | -25.22% |
| 2016 | 299.24 Million TWD | 146.47% |
| 2015 | 121.41 Million TWD | 86.52% |
| 2014 | 65.09 Million TWD | -22.16% |
| 2013 | 83.62 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.91 Billion TWD | -19.03% |
| 2024 Q1 | 2.35 Billion TWD | 21.47% |
| 2023 Q2 | 1.95 Billion TWD | 0.2% |
| 2023 FY | 1.94 Billion TWD | -4.24% |
| 2023 Q4 | 1.94 Billion TWD | -6.28% |
| 2023 Q1 | 1.94 Billion TWD | -3.98% |
| 2023 Q3 | 2.07 Billion TWD | 6.2% |
| 2022 Q2 | 1.97 Billion TWD | 1.12% |
| 2022 Q4 | 2.02 Billion TWD | -2.75% |
| 2022 Q3 | 2.08 Billion TWD | 5.35% |
| 2022 Q1 | 1.95 Billion TWD | 2.02% |
| 2022 FY | 2.02 Billion TWD | 5.71% |
| 2021 FY | 1.91 Billion TWD | 9.52% |
| 2021 Q4 | 1.91 Billion TWD | -1.48% |
| 2021 Q1 | 1.63 Billion TWD | -6.55% |
| 2021 Q2 | 1.61 Billion TWD | -1.14% |
| 2021 Q3 | 1.94 Billion TWD | 20.32% |
| 2020 Q4 | 1.75 Billion TWD | 203.64% |
| 2020 Q1 | 528.71 Million TWD | -2.47% |
| 2020 Q2 | 605.89 Million TWD | 14.6% |
| 2020 Q3 | 577 Million TWD | -4.77% |
| 2020 FY | 1.75 Billion TWD | 223.18% |
| 2019 Q1 | 627.8 Million TWD | 137.88% |
| 2019 Q2 | 563.91 Million TWD | -10.18% |
| 2019 FY | 542.12 Million TWD | 105.41% |
| 2019 Q4 | 542.12 Million TWD | -0.94% |
| 2019 Q3 | 547.24 Million TWD | -2.96% |
| 2018 Q4 | 263.91 Million TWD | -9.44% |
| 2018 FY | 263.91 Million TWD | 17.93% |
| 2018 Q3 | 291.42 Million TWD | -9.98% |
| 2018 Q2 | 323.73 Million TWD | 80.41% |
| 2018 Q1 | 179.44 Million TWD | -19.81% |
| 2017 Q4 | 223.78 Million TWD | 38.35% |
| 2017 FY | 223.78 Million TWD | -25.22% |
| 2017 Q1 | 187.57 Million TWD | -37.32% |
| 2017 Q2 | 194.43 Million TWD | 3.66% |
| 2017 Q3 | 161.74 Million TWD | -16.81% |
| 2016 Q3 | 85.58 Million TWD | -34.82% |
| 2016 Q1 | - TWD | -100.0% |
| 2016 FY | 299.24 Million TWD | 146.47% |
| 2016 Q2 | 131.3 Million TWD | 0.0% |
| 2016 Q4 | 299.24 Million TWD | 249.64% |
| 2015 Q4 | 121.41 Million TWD | 0.0% |
| 2015 Q2 | 112.12 Million TWD | 20.12% |
| 2015 Q1 | 93.34 Million TWD | 43.4% |
| 2015 FY | 121.41 Million TWD | 86.52% |
| 2014 FY | 65.09 Million TWD | -22.16% |
| 2014 Q4 | 65.09 Million TWD | 45.06% |
| 2014 Q3 | 44.87 Million TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2013 FY | 83.62 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Apex Biotechnology Corp. | 500.07 Million TWD | -288.404% |
| Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 31.926% |
| Panion & Bf Biotech Inc. | 1.32 Billion TWD | -46.688% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | -6.636% |
| GenMont Biotech Incorporation | 204.05 Million TWD | -851.829% |
| Abnova (Taiwan) Corporation | 69.42 Million TWD | -2697.726% |
| Adimmune Corporation | 3.7 Billion TWD | 47.603% |
| Polaris Group | 1.46 Billion TWD | -32.599% |
| Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -7799.675% |
| UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -2070.475% |
| PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | -720.346% |